Your browser doesn't support javascript.
loading
Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong, Shengli; Yousefi, Hassan; Savage, Isabella Van; Okpechi, Samuel C; Wright, Maryl K; Matossian, Margarite D; Collins-Burow, Bridgette M; Burow, Matthew E; Alahari, Suresh K.
Afiliación
  • Dong S; TYK Medicines, Inc, Zhejiang, People's Republic of China, 313100.
  • Yousefi H; Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, LA, 70112, USA.
  • Savage IV; Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, LA, 70112, USA.
  • Okpechi SC; Tulane University School of Medicine, New Orleans, Louisiana, 70118, USA.
  • Wright MK; Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, LA, 70112, USA.
  • Matossian MD; Tulane University School of Medicine, New Orleans, Louisiana, 70118, USA.
  • Collins-Burow BM; Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.
  • Burow ME; Tulane University School of Medicine, New Orleans, Louisiana, 70118, USA.
  • Alahari SK; Tulane University School of Medicine, New Orleans, Louisiana, 70118, USA.
Mol Cancer ; 21(1): 138, 2022 06 29.
Article en En | MEDLINE | ID: mdl-35768871
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Límite: Animals / Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Límite: Animals / Humans Idioma: En Revista: Mol Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article